Should you buy Myriad Genetics stock? (NasdaqGS:MYGN). Let's see how it does in our automated value investing analysis system.
(Myriad Genetics stock price per share)
||MYGN Fair Price
(based on intrinsic value)
|MYGN Safety Price (based on a variable margin of safety)||$14.99|
|PE Ratio versus Sector||2679% higher than other Healthcare stocks|
|PE Ratio versus Industry||49% lower than other Diagnostics & Research stocks|
|Free Cash Flow Jitter||24%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 5,374,143 shares shorted. With 75,226,605 shares available for purchase and an average trading volume over the past 10 trading days of 805,857, it would take at least 6.669 days for all of the short holders to cover their shorts.
We believe that Myriad Genetics may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Myriad Genetics looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.
Does Myriad Genetics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles